STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...

Immunotherapies, such as immune checkpoint inhibitors, have transformed the treatment of advanced stage cancers. Unlike chemotherapies that kill cancer cells, these drugs help the body’s immune system ...

"Groups such as the American College of Medical Genetics and Genomics can use this study to help determine whether PKD1 and PKD2 should be considered in future recommendations for reporting of ...

Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...

In December 2020, San Francisco-based population genomics firm Helix received the first FDA approval for a whole-exome sequencing platform. The Helix Laboratory Platform offers coverage of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

The main market opportunities lie in expanding Whole Genome Sequencing at birth, rapid growth in Direct to Consumer Testing, advancing sequencing technologies, and overcoming industry barriers.

Due to the extremely rare overlap of mitochondrial DNA depletion syndrome type 3 and pediatric hepatocellular carcinoma, the case presents daunting therapeutic challenges.

Twist Bioscience and Element Biosciences have introduced the Trinity Freestyle Fast Hybridization workflow for Element’s AVITI™ sequencing platforms.